Does a novel risk assessment model improve the stratification of cancer-associated thrombosis risk compared to the original Khorana Score in patients with cancer?
A novel risk assessment model improves upon the original Khorana Score by better stratifying patients with cancer into high- and low-risk groups for venous thromboembolism at 6 months.
The novel RAM stratified patients with cancer into a high-risk group with 8%-10% cumulative incidence of VTE and 7% PE/LE-DVT at 6 months (v 3% and 2%, respectively, in the low-risk group). The model had improved performance over the original KS and doubled the number of VTE events in the high-risk stratum. We encourage additional external validation from prospective studies.Media: see text.
Li et al. (Tue,) studied this question.